Previous results from our group suggested that the BAVC regimen (BCNU, ARA-C, amsacrine, etoposide) 1 followed by autologous bone marrow transplantation (ABMT) using PML-RARA-negative stem cells could induce a prolonged second molecular remission (CRm) 2 in patients with acute promyelocytic leukemia (APL). In that study, six of seven patients transplanted in CRm were disease-free, while all patients who were not in CRm at the time of transplant relapsed within 9 months. Although the number of patients was low, we felt that APL patients achieving second hematologic complete remission (CR), who were still PML-RARA-positive on PCR did not benefit from ABMT, whereas patients in second CR who were also in CRm could be potentially cured with ABMT. 3, 4 Subsequently, nine more patients in second CRm underwent ABMT after the same salvage treatment used for the first seven patients. Detailed characteristics of these 16 patients are shown in Table 1 . Five were male, the median age was 35 years (range, 9-61), and the median interval between second CRm and ABMT was 2 months (range, 1-5). The PML-RARA junction types were Bcr 1 in nine, Bcr 3 in six and Bcr 2 in one.
Seven patients relapsed at a median of 5 months after ABMT, eight patients are in CRm with at a median of 102 months after ABMT, and one patient died from secondary leukemia 3 years after ABMT. The 10-year projected probability of overall and diseasefree survival is 68 and 56%, respectively. The outcome of the second group of nine patients was much less favorable than the first group of seven; six of whom are still in CRm at a median of 108 months (range, 92-129). In contrast, six of nine patients treated subsequently have already relapsed.
The two groups of patients are comparable in terms of therapy used to achieve second CRm, duration of first CR, second mCR-ABMT interval, source of stem cells, and the conditioning regimen. The only difference is that all patients in the second group had received ATRA-containing treatment at presentation. It is possible that relapse after ATRA-containing induction 5 represented more aggressive disease.
In conclusion, we have not able to reproduce the good results previously achieved and reported using ABMT for APL in second CRm. The optimum consolidation therapy for APL patients in second CRm remains to be determined. 
